ANVS (Annovis Bio) ROC % : 0.00% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Annovis Bio's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 0.00%.

As of today (2024-12-12), Annovis Bio's WACC % is 11.08%. Annovis Bio's ROC % is -1660.16% (calculated using TTM income statement data). Annovis Bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Annovis Bio ROC % Historical Data

The historical data trend for Annovis Bio's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio ROC % Chart

Annovis Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROC %

Get a 7-Day Free Trial

-236.04

-1,485.91

-25,882.18

Annovis Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROC %	Get a 7-Day Free Trial															-2,235.04	-17,512.79	-17,954.02	-	-

Annovis Bio ROC % Calculation

Annovis Bio's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-45.035 * ( 1 - 0% )	/	( (0	+	0.174)	/ 1 )
=	-45.035	/	0.174
=	-25,882.18 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	36.022	-	7.699	-	( 28.378	-	max(0, 7.699	-	36.022	+	28.378	))
=	0

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.208	-	4.279	-	( 5.755	-	max(0, 4.279	-	10.208	+	5.755	))
=	0.174

Annovis Bio's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-17.552 * ( 1 - 0% )	/	( (0	+	0)	/ 1 )
=	-17.552	/	0
=	%

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.046	-	4.057	-	( 3.998	-	max(0, 4.057	-	5.046	+	3.998	))
=	0

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14.362	-	5.391	-	( 12.637	-	max(0, 5.391	-	14.362	+	12.637	))
=	0

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

Annovis Bio (NYSE:ANVS) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Annovis Bio's WACC % is 11.08%. Annovis Bio's ROC % is -1660.16% (calculated using TTM income statement data). Annovis Bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Annovis Bio ROC % Related Terms

Thank you for viewing the detailed overview of Annovis Bio's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Annovis Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

07X:Germany

Address

101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355

Website

https://www.annovisbio.com

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Executives

Henry Iii Hagopian	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White	director	227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck	director	4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini	director, officer: President and CEO	1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy	director	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty	officer: Chief Financial Officer	360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M.	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831